Biomarkers and Associated Immune Mechanisms for Early Detection and Therapeutic Management of Sepsis

키워드

참고문헌 (132)

1. Rhee C, "Incidence and trends of sepsis in us hospitals using clinical vs claims data, 2009–2014", JAMA, 318, pp.1241~1249 (2017)
2. Rudd KE, "Global, regional, and national sepsis incidence and mortality, 1990–2017 : analysis for the Global Burden of Disease Study", Lancet, 395, pp.200~211 (2020)
3. Bone RC, "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis", Chest, 101, pp.1644~1655 (1992)
4. Singer M, "The third international consensus definitions for sepsis and septic shock(sepsis-3)", JAMA, 315, pp.801~810 (2016)
5. Jeganathan N, "The characteristics and impact of source of infection on sepsis-related ICU outcomes", J Crit Care, 41, pp.170~176 (2017)
6. Sinha M, "Emerging technologies for molecular diagnosis of sepsis", Clin Microbiol Rev, 31, pp.e00089~ (2018)
7. Miller RR 3rd, "Validation of a host response assay, septicyte lab, for discriminating sepsis from systemic inflammatory response syndrome in the ICU", Am J Respir Crit Care Med, 198, pp.903~913 (2018)
8. Rhee C, "Diagnosing sepsis is subjective and highly variable : a survey of intensivists using case vignettes", Crit Care, 20, pp.89~ (2016)
9. Seymour CW, "Time to treatment and mortality during mandated emergency care for sepsis", N Engl J Med, 376, pp.2235~2244 (2017)
10. Kahn JM, "Association between state-mandated protocolized sepsis care and in-hospital mortality among adults with sepsis", JAMA, 322, pp.240~250 (2019)
11. Rhodes A, "Surviving sepsis campaign : international guidelines for management of sepsis and septic shock : 2016", Crit Care Med, 45, pp.486~552 (2017)
12. Angus DC, "The search for effective therapy for sepsis : back to the drawing board", JAMA, 306, pp.2614~2615 (2011)
13. Liu VX, "The timing of early antibiotics and hospital mortality in sepsis", Am J Respir Crit Care Med, 196, pp.856~863 (2017)
14. Kumar A, "Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock", Crit Care Med, 34, pp.1589~1596 (2006)
15. Seymour CW, "Assessment of clinical criteria for sepsis : for the third international consensus definitions for sepsis and septic shock(sepsis-3)", JAMA, 315, pp.762~774 (2016)
16. 조성연, "Biomarkers of Sepsis", Infection and Chemotherapy, 46(1), pp.1~12 (2014), 대한감염학회[DOI]
17. Henriquez-Camacho C, "Biomarkers for sepsis", BioMed Res Int, 2014, pp.547818~ (2014)
18. Anush MM, "Role of C-reactive protein as an indicator for determining the outcome of sepsis", Indian J Crit Care Med, 23, pp.11~14 (2019)
19. Mustafić S, "Diagnostic and prognostic value of procalcitonin in patients with sepsis", Med Glas(Zenica), 15, pp.93~100 (2018)
20. Yunus I, "The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics", PLoS One, 13, pp.e0206527~ (2018)
21. Szederjesi J, "An evaluation of serum procalcitonin and c-reactive protein levels as diagnostic and prognostic biomarkers of severe sepsis", J Crit Care Med(Targu Mures), 1, pp.147~153 (2015)
22. Chousterman BG, "Ly6chigh monocytes protect against kidney damage during sepsis via a CX3CR1-dependent adhesion mechanism", J Am Soc Nephrol, 27, pp.792~803 (2016)
23. Xiu F, "C-C chemokine receptor type 2 expression on monocytes before sepsis onset is higher than that of postsepsis in septic burned patients : a new predictor for sepsis in burned injury", Ann Surg, 264, pp.392~398 (2016)
24. Nemeth ZH, "Chemokine receptor CCR2-expressing inflammatory monocytes contribute to the exacerbated inflammatory response associated with sepsis", J Am Coll Surg, 221, pp.S40~ (2015)
25. Pachot A, "Decreased expression of the fractalkine receptor CX3CR1 on circulating monocytes as new feature of sepsis-induced immunosuppression", J Immunol, 180, pp.6421~6429 (2008)
26. Lerman YV, "Sepsis lethality via exacerbated tissue infiltration and TLR-induced cytokine production by neutrophils is integrin α3β1-dependent", Blood, 124, pp.3515~3523 (2014)
27. Jämsä J, "Neutrophil CD64, C-reactive protein, and procalcitonin in the identification of sepsis in the ICU-Post-test probabilities", J Crit Care, 43, pp.139~142 (2018)
28. Mahmoodpoor A, "Flow cytometry of CD64, HLA-DR, CD25, and TLRs for diagnosis and prognosis of sepsis in critically ill patients admitted to the intensive care unit : a review article", Anesth Pain Med, 8, pp.e83128~ (2018)
29. Faix JD, "Biomarkers of sepsis", Crit Rev Clin Lab Sci, 50, pp.23~36 (2013)
30. Moran JL, "Reconsidering lactate as a sepsis risk biomarker", PLoS One, 12, pp.e0185320~ (2017)
31. 강하은, "Lactate as a Biomarker for Sepsis Prognosis?", Infection and Chemotherapy, 48(3), pp.252~253 (2016), 대한감염학회
32. Ganesh K, "A profile of metabolic acidosis in patients with sepsis in an Intensive Care Unit setting", Int J Crit Illn Inj Sci, 6, pp.178~181 (2016)
33. Zhang Z, "Effectiveness of sodium bicarbonate infusion on mortality in septic patients with metabolic acidosis", Intensive Care Med, 44, pp.1888~1895 (2018)
34. Póvoa P, "C-reactive protein as an indicator of sepsis", Intensive Care Med, 24, pp.1052~1056 (1998)
35. Wang HE, "High-sensitivity C-reactive protein and risk of sepsis", PLoS One, 8, pp.e69232~ (2013)
36. Yeh CF, "Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification : a systematic review and meta-analysis", Ann Intensive Care, 9, pp.5~ (2019)
37. Nargis W, "Procalcitonin versus C-reactive protein : usefulness as biomarker of sepsis in ICU patient", Int J Crit Illn Inj Sci, 4, pp.195~199 (2014)
38. Wang H, "Targeting HMGB1 in the treatment of sepsis", Expert Opin Ther Targets, 18, pp.257~268 (2014)
39. Stevens NE, "Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes", Sci Rep, 7, pp.5850~ (2017)
40. Wang X, "Neutrophil CD64 expression as a diagnostic marker for sepsis in adult patients : a meta-analysis", Crit Care, 19, pp.245~ (2015)
41. Lerman YV, "Neutrophil migration under normal and sepsis conditions", Cardiovasc Hematol Disord Drug Targets, 15, pp.19~28 (2015)
42. Sarangi PP, "Role of β1 integrin in tissue homing of neutrophils during sepsis", Shock, 38, pp.281~287 (2012)
43. Ngo LY, "Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis", J Infect Dis, 209, pp.109~119 (2014)
44. Andonegui G, "Targeting inflammatory monocytes in sepsis-associated encephalopathy and long-term cognitive impairment", JCI Insight, 3, pp.e99364~ (2018)
45. Trzeciak A, "Long-term microgliosis driven by acute systemic inflammation", J Immunol, 203, pp.2979~2989 (2019)
46. 이명수, "Tissue-specific Role of CX3CR1 Expressing Immune Cells and Their Relationships with Human Disease", Immune Network, 18(1), pp.1~19 (2018), 대한면역학회[DOI]
47. Friggeri A, "Decreased CX3CR1 messenger RNA expression is an independent molecular biomarker of early and late mortality in critically ill patients", Crit Care, 20, pp.204~ (2016)
48. Ancuta P, "Fractalkine preferentially mediates arrest and migration of CD16+ monocytes", J Exp Med, 197, pp.1701~1707 (2003)
49. Tan RS, "TLR cross-talk confers specificity to innate immunity", Int Rev Immunol, 33, pp.443~453 (2014)
50. Kawasaki T, "Toll-like receptor signaling pathways", Front Immunol, 5, pp.461~ (2014)
51. Kanamaru T, "Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease", Brain Res, 1605, pp.49~58 (2015)
52. Yarovinsky F, "TLR11 activation of dendritic cells by a protozoan profilin-like protein", Science, 308, pp.1626~1629 (2005)
53. Matta BM, "Alarmins and their receptors as modulators and indicators of alloimmune responses", Am J Transplant, 17, pp.320~327 (2017)
54. Moon H. Nahm, "NOD-Like Receptors in Infection, Immunity, and Diseases", Yonsei Medical Journal, 57(1), pp.5~14 (2016), 연세대학교의과대학[DOI]
55. von Kügelgen I, "Pharmacology and structure of P2Y receptors", Neuropharmacology, 104, pp.50~61 (2016)
56. 노종성, "Damage-Associated Molecular Patterns in Inflammatory Diseases", Immune Network, 18(4), pp.1~14 (2018), 대한면역학회[DOI]
57. Tidswell M, "Phase 2 trial of eritoran tetrasodium(E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis", Crit Care Med, 38, pp.72~83 (2010)
58. Rice TW, "A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis", Crit Care Med, 38, pp.1685~1694 (2010)
59. Savva A, "Targeting Toll-like receptors : promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases", Front Immunol, 4, pp.387~ (2013)
60. Mogensen TH, "Pathogen recognition and inflammatory signaling in innate immune defenses", Clin Microbiol Rev, 22, pp.240~273 (2009)
61. Yanai H, "The IRF family of transcription factors : Inception, impact and implications in oncogenesis", OncoImmunology, 1, pp.1376~1386 (2012)
62. Nagar A, "Inflammasome and caspase-1 activity characterization and evaluation : an imaging flow cytometer-based detection and assessment of inflammasome specks and caspase-1 activation", J Immunol, 202, pp.1003~1015 (2019)
63. Nilsberth C, "The role of interleukin-6 in lipopolysaccharide-induced fever by mechanisms independent of prostaglandin E2", Endocrinology, 150, pp.1850~1860 (2009)
64. Aderka D, "Role of tumor necrosis factor in the pathogenesis of intravascular coagulopathy of sepsis : potential new therapeutic implications", Isr J Med Sci, 27, pp.52~60 (1991)
65. Zeni F, "Anti-inflammatory therapies to treat sepsis and septic shock : a reassessment", Crit Care Med, 25, pp.1095~1100 (1997)
66. Cohen J, "INTERSEPT : an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis", Crit Care Med, 24, pp.1431~1440 (1996)
67. Polk HC Jr, "A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients", Am J Surg, 163, pp.191~196 (1992)
68. Mastellos DC, "Clinical promise of next-generation complement therapeutics", Nat Rev Drug Discov, 18, pp.707~729 (2019)
69. Ricklin D, "Complement in disease : a defence system turning offensive", Nat Rev Nephrol, 12, pp.383~401 (2016)
70. Markiewski MM, "Complexity of complement activation in sepsis", J Cell Mol Med, 12, pp.2245~2254 (2008)
71. Ram S, "Infections of people with complement deficiencies and patients who have undergone splenectomy", Clin Microbiol Rev, 23, pp.740~780 (2010)
72. Ricklin D, "New milestones ahead in complement-targeted therapy", Semin Immunol, 28, pp.208~222 (2016)
73. Simmons J, "The coagulopathy of acute sepsis", Curr Opin Anaesthesiol, 28, pp.227~236 (2015)
74. Engelmann B, "Thrombosis as an intravascular effector of innate immunity", Nat Rev Immunol, 13, pp.34~45 (2013)
75. Fiusa MM, "Causes and consequences of coagulation activation in sepsis : an evolutionary medicine perspective", BMC Med, 13, pp.105~ (2015)
76. Camicia G, "Neutrophil extracellular traps in sepsis", Shock, 42, pp.286~294 (2014)
77. Iba T, "The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation", Thromb Res, 131, pp.383~389 (2013)
78. Iba T, "Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation : a prospective multicenter survey", Thromb Res, 130, pp.e129~ (2012)
79. Vincent JL, "Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy : the scarlet randomized clinical trial", JAMA, 321, pp.1993~2002 (2019)
80. Kolaczkowska E, "Neutrophil recruitment and function in health and inflammation", Nat Rev Immunol, 13, pp.159~175 (2013)
81. Soehnlein O, "Direct and alternative antimicrobial mechanisms of neutrophil-derived granule proteins", J Mol Med(Berl), 87, pp.1157~1164 (2009)
82. Lakhan SE, "Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke", Front Neurol, 4, pp.32~ (2013)
83. Chou SH, "Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage", Transl Stroke Res, 2, pp.600~607 (2011)
84. Shaul ME, "Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation : a transcriptomics analysis of pro-vs. antitumor TANs", OncoImmunology, 5, pp.e1232221~ (2016)
85. Martinez FO, "The M1 and M2 paradigm of macrophage activation : time for reassessment", F1000Prime Rep, 6, pp.13~ (2014)
86. Ferreira da Mota NV, "Immunophenotyping of monocytes during human sepsis shows impairment in antigen presentation : a shift toward nonclassical differentiation and upregulation of FCγRi-receptor", Shock, 50, pp.293~300 (2018)
87. Gasco S, "Inflammatory and non-inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis", PLoS One, 12, pp.e0184626~ (2017)
88. Shi C, "Monocyte recruitment during infection and inflammation", Nat Rev Immunol, 11, pp.762~774 (2011)
89. Burgess M, "CX3CR1 expression identifies distinct macrophage populations that contribute differentially to inflammation and repair", Immunohorizons, 3, pp.262~273 (2019)
90. Ishida Y, "Essential involvement of CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis", J Immunol, 181, pp.4208~4218 (2008)
91. Nathan C, "Metchnikoff's legacy in 2008", Nat Immunol, 9, pp.695~698 (2008)
92. Kierdorf K, "Development and function of tissue resident macrophages in mice", Semin Immunol, 27, pp.369~378 (2015)
93. Lavin Y, "Regulation of macrophage development and function in peripheral tissues", Nat Rev Immunol, 15, pp.731~744 (2015)
94. Epelman S, "Origin and functions of tissue macrophages", Immunity, 41, pp.21~35 (2014)
95. Shaw TN, "Tissue-resident macrophages in the intestine are long lived and defined by TIM-4 and CD4 expression", J Exp Med, 215, pp.1507~1518 (2018)
96. Zhao Y, "The origins and homeostasis of monocytes and tissue-resident macrophages in physiological situation", J Cell Physiol, 233, pp.6425~6439 (2018)
97. Loyher PL, "Macrophages of distinct origins contribute to tumor development in the lung", J Exp Med, 215, pp.2536~2553 (2018)
98. Poh AR, "Targeting macrophages in cancer : from bench to bedside", Front Oncol, 8, pp.49~ (2018)
99. Dixon LJ, "Kupffer cells in the liver", Compr Physiol, 3, pp.785~797 (2013)
100. Ju C, "Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice", Chem Res Toxicol, 15, pp.1504~1513 (2002)
101. Nagy LE, "Recent insights into the role of the innate immune system in the development of alcoholic liver disease", Exp Biol Med(Maywood), 228, pp.882~890 (2003)
102. Hutchins NA, "Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1", J Leukoc Biol, 94, pp.963~970 (2013)
103. Hutchins NA, "Kupffer cells protect liver sinusoidal endothelial cells from Fas-dependent apoptosis in sepsis by down-regulating gp130", Am J Pathol, 182, pp.742~754 (2013)
104. Weinhard L, "Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction", Nat Commun, 9, pp.1228~ (2018)
105. Miyamoto A, "Microglia contact induces synapse formation in developing somatosensory cortex", Nat Commun, 7, pp.12540~ (2016)
106. Thion MS, "Microglia and early brain development : an intimate journey", Science, 362, pp.185~189 (2018)
107. Russo MV, "Immune surveillance of the CNS following infection and injury", Trends Immunol, 36, pp.637~650 (2015)
108. Hotchkiss RS, "The sepsis seesaw : tilting toward immunosuppression", Nat Med, 15, pp.496~497 (2009)
109. Delano MJ, "The immune system's role in sepsis progression, resolution, and long-term outcome", Immunol Rev, 274, pp.330~353 (2016)
110. Fullerton JN, "Resolution of inflammation : a new therapeutic frontier", Nat Rev Drug Discov, 15, pp.551~567 (2016)
111. Mariño G, "Self-consumption : the interplay of autophagy and apoptosis", Nat Rev Mol Cell Biol, 15, pp.81~94 (2014)
112. Gump JM, "Autophagy and apoptosis : what is the connection", Trends Cell Biol, 21, pp.387~392 (2011)
113. Green DR, "The clearance of dying cells : table for two", Cell Death Differ, 23, pp.915~926 (2016)
114. Elliott MR, "Efferocytosis signaling in the regulation of macrophage inflammatory responses", J Immunol, 198, pp.1387~1394 (2017)
115. Korns D, "Modulation of macrophage efferocytosis in inflammation", Front Immunol, 2, pp.57~ (2011)
116. Needham DM, "Improving long-term outcomes after discharge from intensive care unit : report from a stakeholders' conference", Crit Care Med, 40, pp.502~509 (2012)
117. Mehlhorn J, "Rehabilitation interventions for postintensive care syndrome : a systematic review", Crit Care Med, 42, pp.1263~1271 (2014)
118. Huang M, "Needham DMNational Institutes of Health, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Psychiatric symptoms in acute respiratory distress syndrome survivors: a 1-year national multicenter study", Crit Care Med, 44, pp.954~965 (2016)
119. Iwashyna TJ, "Long-term cognitive impairment and functional disability among survivors of severe sepsis", JAMA, 304, pp.1787~1794 (2010)
120. Pandharipande PP, "Long-term cognitive impairment after critical illness", N Engl J Med, 369, pp.1306~1316 (2013)
121. Greenhalgh AD, "Peripherally derived macrophages modulate microglial function to reduce inflammation after CNS injury", PLoS Biol, 16, pp.e2005264~ (2018)
122. Getts DR, "Ly6c+inflammatory monocytes are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis", J Exp Med, 205, pp.2319~2337 (2008)
123. Shankar-Hari M, "Understanding long-term outcomes following sepsis : implications and challenges", Curr Infect Dis Rep, 18, pp.37~ (2016)
124. Sun A, "Association between index hospitalization and hospital readmission in sepsis survivors", Crit Care Med, 44, pp.478~487 (2016)
125. Jones TK, "Post-acute care use and hospital readmission after sepsis", Ann Am Thorac Soc, 12, pp.904~913 (2015)
126. Riché F, "Protracted immune disorders at one year after ICU discharge in patients with septic shock", Crit Care, 22, pp.42~ (2018)
127. Chan LC, "Innate immune memory contributes to host defense against recurrent skin and skin structure infections caused by methicillin-resistant staphylococcus aureus", Infect Immun, 85, pp.e00876~ (2017)
128. Chang YH, "What vaccination studies tell us about immunological memory within the innate immune system of cultured shrimp and crayfish", Dev Comp Immunol, 80, pp.53~66 (2018)
129. Gourbal B, "Innate immune memory : an evolutionary perspective", Immunol Rev, 283, pp.21~40 (2018)
130. Boraschi D, "Innate immune memory : time for adopting a correct terminology", Front Immunol, 9, pp.799~ (2018)
131. Foster SL, "Gene-specific control of inflammation by TLR-induced chromatin modifications", Nature, 447, pp.972~978 (2007)
132. Wendeln AC, "Innate immune memory in the brain shapes neurological disease hallmarks", Nature, 556, pp.332~338 (2018)

관련 논문AI추천